Merck's (MRK 2.93%) clinical development team needs to wake up.
The pharma giant announced today that the Food and Drug Administration rejected its anesthesia drug Bridion for the second time.
The first rejection was back in 2008 when Schering-Plough still owned the drug. The FDA went against a unanimous recommendation by its advisory committee and rebuffed the drug, requesting additional data on its potential effect on hypersensitivity.
Merck bought Schering-Plough in 2009, started marketing Bridion in more than 50 countries where it's approved for sale, and ran a study to help convince the FDA that the drug was safe.
Rather than providing its blessing, however, the FDA now has "concerns about operational aspects" of the clinical trial. It appears the agency is concerned about a specific clinical trial site that conducted the hypersensitivity study.
Improperly run clinical trials are an inevitable risk of drug development.
Peregrine Pharmaceuticals (NASDAQ: PPHM), for instance, saw its shares plummet 80% after announcing that a company the biotech hired to send out vials used in its non-small-cell lung cancer trial incorrectly coded the bavituximab drug and the placebo. Without knowing which test subject received which drug, data interpretation becomes impossible -- not that Peregrine didn't try.
Vertex Pharmaceuticals (VRTX -0.76%) didn't have any problems running its clinical trial testing VX-809 and Kalydeco, but the first report of its trial data was incorrect due to an error made by a contractor hired to perform statistical analysis. The data were still solid, just not as solid as investors were initially led to believe.
You'd hope the risk of screwing up a clinical trial would be less for a large pharma like Merck than it would be for smaller biotechs, but even pharmas aren't immune to botched trials. The FDA rejected Johnson & Johnson's (JNJ -1.15%) antibiotic ceftobiprole because it didn't feel the company maintained sufficient oversight over its clinical trial sites. This resulted in an arbitration tribunal ordering Johnson & Johnson to hand the drug back to its partner Basilea and pay about $130 million for the screw up.
Merck was light on the details of exactly what the FDA is concerned about, but it doesn't look like it'll get resolved quickly. The FDA delayed a decision on the drug back in March, presumably to get to the bottom of the issue.
Worst case scenario, Merck has to run another clinical trial to prove the drug is safe. Let's just hope it doesn't take another five years to get back in front of the FDA.
